Inflammatory markers tied to better HCC outcomes after nivolumab treatment
Following treatment with nivolumab, a programmed death (PD)-1 inhibitor, the expression of inflammatory markers seems to correlate with better survival and treatment response in hepatocellular carcinoma (HCC) patients, a recent study has shown. This suggests that antitumour inflammatory mechanisms play a role in the action of nivolumab.